Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor

Many studies have illustrated that two types of mutation – deletions in exon 19 and a point mutation in exon 21 (L858R) – have been reported to comprise up to 90% of all activating epidermal growth factor receptor (EGFR) mutations. A point mutation at exon 19 is a rare mutation, and to date there ha...

Full description

Saved in:
Bibliographic Details
Published in:Thoracic cancer 2014-07, Vol.5 (4), p.358-361
Main Authors: Zheng, Hua, Wang, Qunhui, Shi, Heling, Zhang, Hongmei, Hu, Fanbin, Li, Baolan
Format: Article
Language:English
Subjects:
Case Reports
EGFR mutation
Epidermal growth factor
Genes
Lung cancer
Mutation
non‐small cell lung cancer
targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many studies have illustrated that two types of mutation – deletions in exon 19 and a point mutation in exon 21 (L858R) – have been reported to comprise up to 90% of all activating epidermal growth factor receptor (EGFR) mutations. A point mutation at exon 19 is a rare mutation, and to date there have been no reports investigating the sensitivities of EGFR‐tyrosine kinase inhibitors (TKIs) to the mutation. In this case report, we have demonstrated a special mutation, a point mutation at c.2279T>C (p.L760P) in exon 19 of EGFR, which has responded favorably to icotinib in a lung adenocarcinoma patient with brain metastasis. Icotinib is a new type of oral EGFR‐TKI developed in China and is the first EGFR‐TKI in Asia. Icotinib has the potential to improve the prognosis of lung adenocarcinoma patients and with less toxic‐effect.
ISSN:1759-7706
1759-7714
DOI:10.1111/1759-7714.12096